• SPYR Inc. is a Texas-based company dedicated to delivering quality in-demand Internet of Things (“IoT”) products for smart home and auto consumers of Apple products
• The company’s flagship products are developed by subsidiary Applied Magix, which also sources white label Apple HomeKit(TM) products and accessories
• SPYR recently announced evaluation of potential expansion into Mexico, Central Europe and Thailand to extend its global reach beyond its U.S. operations and its representative office in Hong Kong
• The company is also sharply discounting many of its products in a summer sale as it prepares to develop new upgraded versions
• SPYR has also announced that the company is working to develop new Car Play-compatible products

Apple-compatible product developer SPYR (OTCQB: SPYR) is examining opportunities to expand its reach to Latin America, Central Europe and Thailand to grant its smart home and connected car market products a global scale. The Internet of Things (“IoT”) developer already has a representative office in Hong Kong for potential supply of its Apple ecosystem tie-in solutions, which include chargers, adapters and data blockers produced under subsidiary Applied Magix as the source of white label Apple HomeKit(TM) products and accessories, as well as own-brand products. “These are markets that need to be considered for future expansion and we may as well start investigating a foundation now, with an eye towards the future,” SPYR CEO Tim Matula stated (https://ibn.fm/YwuZ4). “Applied Magix’ research and investigative efforts in this direction will help SPYR gain a worldwide footprint and potentially reach many more customers.” The company has been working to increase shareholder value through a number of product upgrades, sales and marketing efforts. “We are constantly upgrading our product pipeline, and our efforts to streamline our inventory benefit our tech-enthusiastic customers by making aggressive discounts available to them during our Summer Sales events,” Applied Magix CEO Harald Zink stated while announcing discounts of more than 50 percent on some of the company’s products in order to move them out ahead of expected improved versions (https://ibn.fm/gZFFT). “As we will continue to support all of our products, our existing customers are protected, as we do not orphan any of our products,” he added. The company announced the launch of its new development initiative to upgrade MagixDrive, the flagship product that is a wireless adapter between iPhones and vehicle CarPlay infotainment systems, in an April 21 news release that also indicated the company is preparing to develop other Car Play products. “Following the success of our MagixDrive Wireless CarPlay adapter, we are now really excited to hint at the next evolution of it, as we’ve listened to customer feedback and are looking at adding new features to this project,” Zink stated (https://ibn.fm/3Z6kd). SPYR is targeting what it regards as a significant market opportunity in creating smart hardware and software solutions exclusively for Apple customers. The company regards Apple customers as a group of consumers willing to pay for the privilege of getting higher quality out of their products, and it notes that there is a dearth of smart devices designed to properly integrate with Apple’s HomeKit. SPYR has also reported that it is evaluating the possibility of acquiring a developer of proprietary lighting technologies for the transportation and industrial industries, and the developer of a proprietary web-based software-hardware package used for asset tracking and management by the construction, agriculture, police and energy industries, among others (https://ibn.fm/ZcWtA). For product information, please see the Applied Magix website at https://AppliedMagix.com, or specific product sites:

• MagixDrive Wireless CarPlay Adapter – https://appliedmagix.com/MagixDriveBundle
• HomeKit Secure Video Camera with iCloud Storage – https://appliedmagix.com/HomeKitCamera
• Multipurpose Sensor with Alarm – https://appliedmagix.com/HomeKitAlarmSensor
• Environment and Motion Sensor – https://appliedmagix.com/HomeKitMotionSensor
• Window and Door Contact Sensor – https://appliedmagix.com/HomeKitContactSensor
• MagixBlock USB DataBlocker – https://appliedmagix.com/MagixBlock
• MagixCharge Dual USB-C Car Charger – https://appliedmagix.com/MagixCharge

For more information, visit the company’s website at www.Spyr.com. NOTE TO INVESTORS: The latest news and updates relating to SPYR are available in the company’s newsroom at https://ibn.fm/SPYR

Alternative Products Expo is coming to Medellín, Colombia, on May 21-22nd 2022. A leading organizer in the alternative industry, they’re committed to serving the community and strive to provide an exciting learning experience in a safe and conducive environment. For one, exhibitors can showcase their products, expand their market reach, and get discovered by investors and industry professionals. Sponsored by JuicyFields.io, this event is expecting 100+ vendors and 1000+ products, including other sponsoring brands such as LightFire & EZ Delta 8 Wholesale. A one-of-a-kind networking event, at Alt Pro Expo, buyers and investors seeking profitable avenues can discover some of the finest products even before they’re launched in the market. These products include Delta 8, nicotine replacements, vapes, CBD, Kratom and other botanicals, mood enhancers, hemp derivatives, energy boosters, and dietary supplements, to name a few. Alternative Products Expo offers a viable platform for building professional ties and connecting with a wider audience. Its mother company, ZJ Events, is a pioneer in organizing high-quality trade shows where each conversation leads to a potential business opportunity. After hosting a series of trade shows at top US cities, they now arrive in Medellin, where they’re fostering the local and budding alternative market! Become a part of this ever-growing community and join us at the next Alternative Products Expo in Medellín! To learn more, or to purchase your tickets, please visit altproexpo.com.

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Over 80% of PD patients(2) and 75% of AD patients(3) experience dysphagia. According to Dr. Jay Blankenship, Zylö Therapeutics V.P. of Business Development, “ketamine is an incredibly versatile drug that continues to show promise with new therapeutic indications.”  Eric Weisblum, CEO of Silo Pharma believes “the ability to deliver ketamine (through the skin) in a time-released manner will allow us to explore both the safety and efficacy of our therapeutics … We believe that Zylo’s patented technology will allow us to reach potential patients that suffer with dysphagia.” Currently, ketamine is administered intravenously, via bone tissue (intraosseous), intramuscularly, orally or intranasally (through the nose), methods that are impractical, painful and sometimes subject to nausea.(4) Ketamine has been available for over “half a century … first synthesized in 1962 by Calvin Stevens at Parke-Davis Co (now Pfizer) as an alternative anesthetic to phencyclidine.” Ketamine facilitates “hypnotic (sleep-producing), analgesic (pain-relieving) and amnesic (short-term memory loss) effects; no other drug used in clinical practice produces these three important effects at the same time. Ketamine is a standard in operating rooms. Due to its “bronchial dilatory profile,” ketamine is the safer choice for patients with “asthma and life-threatening acute bronchial constriction,” and is “preferred in patients with unstable hemodynamics (blood flow). Ketamine is also one of the very few drugs approved for anesthesia induction in caesarean sections. It is considered the agent of choice in children and burn victims.” () Novel ketamine uses show promise in treating PD-related depression as well as dyskinesia, resulting from the side effects of levodopa treatments. Dyskinesia includes involuntary, erratic, writhing movements of the face, arms, legs, and/or trunk. “Recent clinical findings suggest that ketamine may provide neuroprotection and reduce neuropsychiatric symptoms associated with AD.”() Neuropsychiatric symptoms include agitation, depression, apathy, delusions, hallucinations, and sleep impairment. Ketamine has also been studied to battle suicide ideation, as well as “eating disorders, problematic substance use, post-traumatic stress and anxiety…”() In October 2021, Silo entered into a sponsored research agreement with Columbia University incorporating the work of Dr. Christine Ann Denny. According to a Silo Pharma news release, “Dr. Denny’s pioneering research into whether ketamine … may improve memory retrieval, halt, or even reverse, the process of Alzheimer’s disease-related to memory loss or cognitive aging, could have life-altering implications for people suffering with everything from Alzheimer’s disease to post-traumatic stress disorder (‘PTSD’).” Weisblum said, “to be able to bring hope and possibly a therapeutic to patients suffering from Alzheimer’s disease (and potentially other ailments) is an exciting proposition for Silo Pharma. The unique compounds being developed at Columbia have shown great promise, and we look forward to continuing to explore and develop these therapeutics.” Illustration courtesy of Zylö Therapeutics. For Silo Pharma’s most recent news, click here. Silo Pharma 560 Sylvan Avenue, Suite 3160 Englewood Cliffs, NJ 07632 For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer
• CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier
• Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients
• The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there
• An April 14 Virtual Investor Spotlight Event provided investors with information on CNS’s efforts, and the Zoom webcast will remain viewable through July for interested parties

Investors interested in potentially getting on board with a biopharmaceutical company working to develop novel brain cancer solutions can learn about the unmet need for treating deadly glioblastoma (“GBM”) and the work CNS Pharmaceuticals (NASDAQ: CNSP) is putting into granting GBM patients new hope by reviewing a recent Virtual Investor Spotlight Event that will be viewable for the next few weeks. The spotlight event (event can be accessed at https://ibn.fm/QhlSJ, presented by corporate and private client services advisors at JTC IR showcases CNS’s novel anthracycline Berubicin, which appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier in targeting tumors of the central nervous system. Neuro-oncologist opinion leader Samuel A. Goldlust, M.D., joined CNS Pharmaceuticals CEO John Climaco for the live Web event April 14, which was recorded for on-demand access through July (https://ibn.fm/7j4DD). Dr. Goldlust currently serves as the Pitkin Chair in Neuro-Oncology and the Medical Director of the Brain and Spine Institute at the John Theurer Cancer Center, and is an investigator in CNS’s global Berubicin study. Berubicin was the drug candidate subject of a small-scale Phase 1 clinical trial in 2006 that evaluated Berubicin’s safety, which was notable because one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent 16 years. Nearly half of the trial’s patients experienced a statistically significant improvement in clinical benefit (https://ibn.fm/6Llns). GBM patients in general have a median survival rate of only 14.6 months after diagnosis, which is evidence of the need for an effective treatment for the thus-far incurable cancer. Anthracyclines like Berubicin are among the most powerful chemotherapy drugs and are effective against more types of cancer than any other class of chemotherapeutic agents, according to the company. They are designed to utilize natural processes to cause deoxyribonucleic acid (“DNA”) damage in targeted cancer cells by interfering with the action of cell-growth enzyme topoisomerase II. The potentially pivotal global trial that is currently under way began recruiting and dosing patients in the United States with Berubicin in 21-day cycles last year, and governmental approvals in European countries are advancing efforts to begin recruitment there (https://ibn.fm/pSXOP). Ultimately, more than 200 adult patients will participate in the “adaptive, multicenter, open-label, randomized and controlled study.” The company expects to report an interim analysis of its results early next year when 50 percent of the patients have reached the six-month point in their dosing regimen. Primary completion of the study is anticipated by October 2024, with final completion expected by February 2025 (https://ibn.fm/4DVcX). CNS is also in the process of developing a drug candidate labeled WP1244, which uses anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than chemotherapy agent daunorubicin in stopping tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity, according to the company, making WP1244 worth evaluating for treating brain cancers, as well as pancreatic and ovarian cancers and lymphomas. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Fan Pass Live with Artist Republik and FeaturedX is creating a 360 platform with pricing that sets them apart from competitors
• The May contest on Instagram is underway, and features Grow with Us (“GWU”) campaigns to help artists build their fanbase on Spotify/Soundcloud
• In the first 100 days, positive growth has been reflected across revenue per subscriber, spend per customer, and subscriber lifetime value
• Key metrics for social media have also seen an increase across the board

In the five months since announcing the acquisition of Artist Republik (and FeaturedX), Friendable (OTC: FDBL), and its flagship offering, Fan Pass Live artist platform, has seen increased growth in several areas, including social media reach, artist recruitment, and fan subscriptions – among other metrics. The combination of services has provided Friendable with the first 360 artist platform offering, resulting in a one-of-a-kind “anti-label” movement. Other platforms advertise a complete independent artist offering, but none compare to the offering provided by Friendable through Fan Pass Live, Artist Republik, and FeaturedX. Fan Pass Live took to Instagram (@fanpasslive) to let artists know exactly what sets them apart from their competitors:

• Price: $5.00 (Single), $11.00 (Album), $14.99 (Subscription)
• Annual Fee: $0
• Royalties Paid to Artists: 100%
• IRSC and UPC: FREE
• Promotions: Social Links, Playlisting, PR, Distribution, Ticketed Live Streaming, Revenue Building, Websites, and More

Each month, Fan Pass Live offers its artists additional revenue opportunities through contests that are posted on Instagram. For May, Fan Pass Live wants to help artists grow their fanbase. The top three artists with the highest streaming time in May will win free fan growth (Grow with Us) campaigns on Spotify/Soundcloud. First place will receive a $100 GWU campaign; second place will receive a $50 GWU campaign; third place will receive a $25 GWU campaign. Additionally, when an artist promotes three streams on Instagram and tags Fan Pass Live, they can win a free promo design (https://ibn.fm/mE4wy). Recent key metrics reported by the company about the first 100 days of growth for the year (per stripe merchant reporting) included revenue per subscriber increasing by 107.3% (an average of $10.72 per subscriber), spend per customer increasing 28.3% (an average of $34.12 per customer), and subscriber lifetime value (“LTV”) increased 168.5% (an average LTV of $214.45). “The reward of seeing results continues to motivate and point our team in the right direction, as our collective efforts of testing, iterating, testing, testing, and more testing pay off,” Friendable CEO Robert A. Rositano Jr. stated (https://ibn.fm/cgGnb). “We must constantly look at the macro vision and direction, but it’s the micro-levels of detail that provide the most valuable data as we seek the next milestones in artist sign-ups, fan engagement, and conversions to purchases of all kinds, which is what the above results are showing us.” The most recently reported social media statistics show key growth for March 2022 over February 2022:

• New Customers – increased by 55.6%
• New Subscribers – increased by 38%
• Spend per Customer – increased by 5.2%
• Revenue per Subscriber – increased by 4.2%
• Subscriber Lifetime Value – increased by 23.5%
• Subscriber Churn/Cancelation Rate – decreased by 15.6%

In an April press release discussing these metrics (https://ibn.fm/55uxk), (https://ibn.fm/OSl5n), Rositano Jr. stated that “From social media to revenue and user increases, as well as steady growth in key categories, it tells us everything we need to know about the path we are on as a Company, platform, team, and community of fledgling artists, fans and investors all seeking to facilitate the launch and discovery of artists worldwide as we build a brand that stands alongside each one.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance
• Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment
• Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs
• It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation

Lexaria Bioscience (NASDAQ: LEXX), since its inception, has been pushing the boundaries of drug delivery. Through its patented technology, DehydraTECH(TM), the company has achieved more efficient delivery of active pharmaceutical ingredients into the bloodstream while also increasing their bioavailability. Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the delivery of cannabinoids, nicotine, antivirals, PDE5 inhibitors, and more. In March 2022, the company announced that it would begin a human clinical study, NIC-H22-1, focused on oral nicotine alternatives to replace smoking. The study would involve 36 participants and compare DehydraTECH’s nicotine pouch performance with existing brands on the market. In a previous animal study, the DehydraTECH-nicotine proved to deliver peak nicotine performance to the bloodstream 10 to 20 times faster than the study’s controls (https://ibn.fm/GI3R4). Lexaria is also in the process of a clinical human study, HYPER-H21-4, to determine the effectiveness of DehydraTECH-CBD for hypertension treatment. Involving 60 participants, this ranks as one of the most comprehensive studies undertaken by Lexaria and is a significant step for the company as it seeks Investigational New Drug (“IND”) approval by the United States Food and Drug Administration (“FDA”). Results are expected in Q3 2022 (https://ibn.fm/rLyN3). Lexaria has also made significant progress using its technology for the enhanced delivery of antiviral drugs. On April 26, 2022, it received its 25th patent granted worldwide in what Chris Bunka, the Chief Executive Officer (“CEO”) of the company, referred to as “Another validation of the versatility of our DehydraTECH drug delivery technology” (https://ibn.fm/OhJlO). Earlier in the year, Lexaria also announced commencing the first phase of its epilepsy research program, EPIL-A21-1. The study would assess the seizure-inhibiting activity of CBD administered via the company’s DehydraTECH technology. More specifically, Lexaria aimed to compare its technology to the only FDA-approved CBD-based seizure medication Epidiolex, used to treat seizures associated with two rare forms of pediatric epilepsy- Lennox-Gastaut syndrome and Dravet syndrome (https://ibn.fm/7CnzW). All of Lexaria’s efforts serve to demonstrate the superior performance of both its research program and its DehydraTECH drug delivery technology. By doing so, it is looking to tap into various markets, including but not limited to oral cannabinoids, oral mucosal nicotine, antivirals, human hormones, dementia, rheumatoid disease and diabetes. Lexaria’s management hopes that before the end of the 2022 calendar year, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation to steer the conversation forward and allow for the greater adoption of DehydraTECH. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Dynamic Global Events (“DGE”) invites you to the 2nd Promotional Review Committee (“PRC”) Performance Optimization Summit, regarded as the largest, most detailed PRC conference available. Slated for May 23-25, the three-day online livestream event is designed for all the cross-functional professionals working on review teams, including legal, medical communications, public relations, marketing, product management, brand management, editors, compliance, art, scientific communications, and more. The summit provides PRC best practices for team management and cooperation, maintaining regulatory compliance, and adapting to new technologies and platforms. Promotional review professionals face many challenges as they craft fair and accurate product messages that must conform to all regulations.  Gathering multiple rounds of feedback in a collaborative environment, making sure ad agencies have understood all their guidelines, and anticipating the response of subjective regulatory reviewers was already challenging enough – and now in a post-COVID setting, most of these committees are not even meeting in-person. So, the return of the industry’s largest and most trusted PRC learning event could not have happened at a better time. Last year’s conference was acclaimed as “an excellent event for finding out how others are doing things in the industry” (Head, Promotional Excellence, Sanofi) that featured “topics that were of value and speakers who were very knowledgeable on the topics they presented” (Director, U.S. Advertising & Promotion, AbbVie). (https://ibn.fm/8hOd3). So, attendees at this year’s summit are definitely in for a treat. Attendees will hear from vice presidents, lead counsels, directors, and department heads responsible for regulatory affairs, advertising, promotion, and labeling divisions.   Drawn from organizations such as Turning Point Therapeutics, Takeda, Sanofi, Kyowa Kirin, Abbvie, Otsuka, Merz Aesthetics, Mirati Therapeutics, Merck, Sobi, and more, the 25 featured speakers will take part in panel discussions as well as single-person and joint presentations anchored in three main themes, according to the event brochure. Some of this year’s all-new agenda topics, added to meet audience requests, include PRC strategies for modular content, artificial intelligence, celebrity endorsements, upgrading team training, empowering coordinators, and much more. Overall, the summit will:

• Provide a roadmap for building and maintaining a core claims compendium
• Offer important tactics for digital asset management
• Focus on review and submission methods for modular content
• Discuss detailed compliance strategies for speaker bureaus, celebrity endorsements, streaming video, payer communications, investor media, and more
• Provide key learnings for entire teams

To learn more, please visit https://dgevents.com/event/promotional-review-committee-performance-optimization/

ND Supplies presents the 3-day O’Cannabiz Conference Expo & Awards, June 1-3, 2022, at the Toronto International Centre this year. Voted the No. 1 Cannabis Event in Canada by High Canada Magazine, the O’Cannabiz International Conference returns as an in-person event, after being canceled last year. The event organizers are thankful to the partners, sponsors, and exhibitors for their patience and co-operation. The event is being touted as the most sort after cannabis conference in North America featuring Cannabis trade shows, retail summits, awards functions along with global-level networking opportunities among the veterans and dignitaries of the cannabis spectrum in Canada. Cannabis vendors, creatives, enthusiasts, researchers, regulators, and activists are invited to attend this 3-day event that will witness veterans who travel from the length and breadth of the region to attend this event. Attendees will a true cannabis business experience at this conference that covers a broad spectrum of diverse topics on cannabis offering valuable learning sessions. In a power-packed business-to-business show, young businesses, and aspiring entrepreneurs can leverage this huge platform to build long-term business relations and establish networking ties with peers and thought leaders in the only G7 country to legalize both the medicinal and recreational use of cannabis. At the exhibit portion of the trade show, attendees can visit the exhibitor booths lined in the 50,000-square-foot expo hall, showcasing different facets of the cannabis industry, products, and novel ideas for people to learn and understand. Investors in search of lucrative business opportunities can explore and discover enterprising talent at these booths. The three days of networking opportunities will foster lifetime connections amongst the members of the cannabis community. 3,500+ attendees are expected to grace the event and participate in the 70+ interactive sessions, on a mammoth stage shared by 180+ industry leaders who will reside as speakers to impart valuable tips and strategies on vital topics like cannabis trading and laws, extraction & compliance in Canada., Attendees will receive a grand welcome at the Red Carpet Royalty Cocktail Reception. As a part of the O’Cannabiz Conference, on June 1st, 2022, the 2nd Annual O’Cannabiz Awards Dinner Gala will be hosted by CBC’s Gerry Dee, at Toronto’s Casa Loma to felicitate the dignitaries of the cannabis and recognize their contribution by honoring them with excellence awards. Marijuana activists Tommy Chong and Steve De Angelo will be presented with a Lifetime Achievement Award, and all other award winners will be announced live at the Gala. Enthusiasts, retailers and budtenders can check out the latest retail products at the Retail Summit, dedicated to the point-of-sale side of the cannabis industry. To learn more, please visit https://ocannabiz.com/.

FinovateSpring is a CPE and CPD certified event, hosted by Finovate Group that organizes fintech seminars and events for the last 10 years. This year, FinovateSpring is coming to San Francisco, California, as a live in-person event on May 18-20, 2022. For the first time since 2019, the annual spring fintech conference will feature live, in-person demos, in-person speakers, discussions, panels, and global thought leaders of the financial technology spectrum. This event will be hosting 1,100+ senior attendees, more than 50% of whom are from financial institutions. As a bonus, the show will be graced by representatives of the top 10 banks in the U.S. To attend the event, there will be 50+ demoers, 100+ speakers, 270+ financial institutions, 200+ C-level attendees, and 100+ media personnel, who will cover the event. Finovate events are attended by influential personas of the fintech arena namely investors, decision-makers, regulators, and innovators leading the fintech revolution, who attend these events year after year. They have substantial authority and offer key insights into the future of financial services technology. From showcasing your new fintech solution in front of the Finovate community to collaborations, long-term partnerships, and funding along with making new clientele and getting expert feedback, the FinovateSpring has plenty to offer its attendees. Get live demos from startups, two startup-booster opportunities are being floated this year to help startups gain visibility on this forum. New formats like Fintech Fight Club and Finovate Unicorn Power Panel, along with 30 companies making their Finovate debuts, are some exciting opportunities available for new and small-scale entrepreneurs. Along with the networking scope, attendees get two days of live, in-person fintech demos and 3-days of insightful keynotes, fireside chats, discussions, and debates. The opening speech will be given by Greg Palmer, Vice President, Finovate. Some important keynote discussion and boardroom topics include

• How to win the war for fintech talent-attracting the right manpower
• Why do digital transformation projects generally fail- how to prevent the fallout
• Why diversity matters
• The three C’s of innovation- culture, customer, and connection
• Harnessing new tech to meet the needs of businesses and consumers
• Financial cybercrime and how new technology can harness the fraud

Organizers are taking the requisite steps to comply with COVID-19 guidelines and conduct the Finovate event in a sustainable and socially responsible manner. To learn more, please visit https://informaconnect.com/finovatespring/.

• Visa will provide its extensive network of payment experts to assist LQwD (and other fintech companies) who join the program
• LQwD is currently operating ten global nodes on the Bitcoin Lightning Network – France, England, Sweden, Singapore, Italy, Indonesia, Germany, Ireland, the US, and India
• LQwD launched its proprietary PaaS platform in November 2021, working to lower transaction fees and facilitate faster transaction times
• The cryptocurrency market is expected to reach a value of US $4.94 billion by 2030

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company focused on creating enterprise-grade infrastructure to drive the adoption of Bitcoin, has announced that it has joined Visa’s (NYSE: V) Fintech Fast Track Program. By working with Visa, a world leader in digital payments, LQwD can accelerate bringing Bitcoin to the masses through its subsidiary Coincurve.com, a virtual currency platform, along with its proprietary platform as a service (“PaaS”) offering and global routing nodes (https://ibn.fm/G1yGM). The Visa Fintech Fast Track Program was established for fintech companies to create new and innovative payment solutions through partnership, collaboration, and investment. The program offers fintech companies a payments path that is right for their current endeavors – including the idea, funding, and growth stages. Visa provides these companies with startup incentives, faster onboarding, and dedicated expertise and support. The Visa Fintech North American Fast Track offers:

• Smooth onboarding to Visa’s global network
• Lower expenses from Visa and selected enablement partners
• Referrals to partners based on need
• Payment experts providing the hands-on support and guidance needed to get fintechs up and running

To join the Fast Track Program, LQwD had to fill out an application and meet certain stipulations implemented by Visa, after which it underwent a review process to determine if it qualified for the program. Since approval, LQwD has been able to onboard with Visa and implement the go-to-market strategy. “By joining Visa’s Fast Track program, exciting fintech companies like LQwD gain valuable access to Visa experts, technology, and resources. Fast Track lets us provide new resources that rapidly growing companies need to scale with efficiency,” Visa’s SVP and Global Head of Fintech, Terry Angelos, commented. Shone Anstey, CEO of LQwD, underlined that this was an exciting opportunity for the company. “Our direct relationship with Visa now gives LQwD the advantage of accessing their growing partner network, as well as experts in the payments space. It’s a big benefit,” he added. LQwD currently has ten global nodes operational on the Lightning Network, including France, England, Sweden, Singapore, Italy, Indonesia, Germany, Ireland, the US, and the most recently launched node – India. Altogether, LQwD already has a capacity of over 10 BTC and is growing consistently. In November 2021, in coordination with the launch of its first node (US-West), the company also launched its PaaS platform – https://lqwd.tech/. Since then, the company has focused on scaling the Lighting Network and making Bitcoin transactions possible on a global level with lower fees and faster settlement times, amid growing interest in cryptocurrencies and the Lightning Network worldwide. According to Allied Market Research, the cryptocurrency market was valued at US $1.49 billion in 2020. Growing at a CAGR of 12.8%, the market is expected to reach US $4.94 billion by 2030. The primary drivers for growth are the growing acceptance of these currencies as legal tender and technological advancements (https://ibn.fm/2TTPB). For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF